Join Diane Ramsden, PhD, and Lindsey Whaley, MS, for an inside look at TruVivo™, a novel all-human in vitro hepatocyte system developed by LifeNet Health LifeSciences.
Current in vitro hepatic models, such as sandwich cultures, lose key hepatocellular function and enzymatic activity over time. More advanced co-culture platforms have been introduced but are often complex or contain non-human cells that can alter results due to innate background contribution to metabolism. These limitations make it challenging to characterize human mechanisms for the metabolism of drug candidates, especially those that are slowly metabolized. To address these limitations, TruVivo was developed as the first and only 2D+ hepatic system to provide human-relevant, reliable results in an easy-to-use format.
In this webinar, Lindsey Whaley will introduce key features of the TruVivo system that demonstrate its potential to be an ideal platform for drug discovery and development applications. Diane Ramsden will then present data from her evaluation of TruVivo as a potential tool for investigating mechanistic drug metabolism and pharmacokinetics, including drug-drug interaction potential, and translational risk assessment.
Key Topics Include:
- The advantages of the system – which offers the simplicity of a 2D model, with the robust levels of data typical of 3D models.
- An overview of how TruVivo mimics the microarchitecture and functionality of the human liver.
- How hepatocytes are pre-qualified in the system to reduce variability for a broad range of pharmacological and toxicological applications.
- Drug metabolizing enzyme activity and retention over the use period.
- Translation of in vitro derived parameters to conduct DDI risk assessment.
Presenters
Director
Oncology DMPK
AstraZeneca
Diane Ramsden is a Director and ADME BA group leader within AstraZeneca Oncology. She has worked in the pharmaceutical industry for over 20 years and has a range of experience in project representation from early discovery stage to post marketing in multiple therapeutic and disease areas including Oncology, GI, NS, cardiometabolic, respiratory, immunology and rare diseases and across modalities including small molecule drugs, PROTACs, microbiome-based therapeutics, mAbs, ADCs and RNAi.
Product Manager
LifeSciences
LifeNet Health
As LifeSciences product manager, Lindsey has a passion for driving innovation and delivering exceptional user experiences. Known for her collaborative approach and ability to translate marketing insights into actionable strategies, Lindsey is dedicated to delivering products that align with core customer needs. Lindsey holds a bachelor’s degree in biology and a master’s degree in biotechnology. During her academic journey, she completed two internships at LifeNet Health focused on various LifeSciences marketing projects where she quickly developed a passion for making high-quality, human research solutions accessible to scientific researchers. In her role as Product Manager for LifeNet Health LifeSciences, Lindsey collaborates with cross-functional teams to manage new product releases and an existing portfolio to a global market. She most enjoys using her scientific background to effectively communicate the benefits of LifeSciences’ innovation portfolio to the scientific community.
Production Partner
LifeNet Health LifeSciences
LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.
Additional Content From LifeNet Health LifeSciences
A Novel, All-Human Hepatic Triculture System
Join Edward LeCluyse and Paul Gallant as they offer insight into a novel, all-human hepatic triculture and how this unique system addresses the need for a convenient and human-relevant long-term hepatic culture.
Additional Content From Scientist.com
Fast-Forward Your Custom Antibody Generation With Four Bio-Rad Services
Discover how Bio-Rad's bioanalytical services and SpyTag-SpyCatcher technology can speed up custom antibody generation and improve assay flexibility for challenging targets.
Fully Characterized, Standardized Human Induced Pluripotent Stem Cell Line and Ready-to-Use, High-Quality Neural Progenitor Cells for Downstream Differentiation Applications
In this webinar, experts present a standardized human induced pluripotent stem cell line and its differentiation into neural cells for disease modeling and assay development.
COMPLi HBS Legislation Series: France
This webinar explores France's governance of human biological samples for research, focusing on acquisition, storage, import/export, and unique requirements in comparison to global standards.
Related Content
Save Time and Money When Prioritizing Drug Candidates: Using Cell-Based Reporter Assays for Nuclear Receptor Profiling
Dr. Jack Vanden Heuvel discusses the use of cell-based reporter assays for nuclear receptor profiling to efficiently prioritize drug candidates and minimize off-target effects.
The 3D DILI Model of Success – from Biological Relevance to Industry Application
Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.